NCT00942331
Clinical Trial Information
Trial Number: NCT00942331 (ClinicalTrials.gov)
Disease Type:
- Urothelial Tract Neoplasm - Urothelial Tract/Bladder Cancer
Trial Title:
A Randomized Double-Blinded Phase III Study Comparing Gemcitabine, Cisplatin, and Bevacizumab to Gemcitabine, Cisplatin, and Placebo in Patients With Advanced Transitional Cell Carcinoma
Study ID:
CALGB-90601
Images are available?:
No
Is this a NCI-MATCH Trial?:
No
Datasets Linked to Trial
| Title | Description |
|---|---|
| NCT00942331-D3 | Dataset NCT00942331-D3-Dataset.csv (ae_all) is one of 3 datasets associated with PubMed ID 33989025. This dataset contains adverse event information. |
| NCT00942331-D2 | Dataset NCT00942331-D2-Dataset.csv (dosemod_all) is one of 3 datasets associated with PubMed ID 33989025. This dataset contains dose modification reasons for all patients with at least one dose reduction or delay. There is also a variable distinguishing the dose modification between cisplatin and gemcitabine. |
| NCT00942331-D1 | Dataset NCT00942331-D1-Dataset.csv (pt_all) is one of 3 datasets associated with PubMed ID 33989025. This dataset contains all patient level data including baseline characteristics, survival status and time to event, progression free survival and time to event, treatment summaries, off treatment reasons for chemotherapy and bev/placebo, best response, tumor scans, the occurrence of grade 3/4 thrombocytopenia, the occurrence of a serious adverse event, and the occurrence of a dose delay or reduction. |
Accessibility | Disclaimer | FOIA | HHS Vulnerability Disclosure | Privacy & Security
U.S. Department of Health and Human Services | National Institutes of Health | National Cancer Institute | USA.gov
NIH…Turning Discovery Into Health®